| DrugRepV_0574 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Crimean-Congo hemorrhagic fever virus | IbAr10200, Nigeria | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_0575 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Crimean-Congo hemorrhagic fever virus | ArD39554 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_0576 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Crimean-Congo hemorrhagic fever virus | IbAr10200, Nigeria | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_0577 | Chlorpromazine | Nervous System | Schizophrenia | Crimean-Congo hemorrhagic fever virus | IbAr10200, Nigeria | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_0578 | Chlorpromazine | Nervous System | Schizophrenia | Crimean-Congo hemorrhagic fever virus | ArD39554 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_0579 | Chlorpromazine | Nervous System | Schizophrenia | Crimean-Congo hemorrhagic fever virus | IbAr10200, Nigeria | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_3737 | OSU-03012 | Anticancer | Brain cancer | Crimean-Congo hemorrhagic fever virus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 25986249 |
| DrugRepV_3864 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | Afg-09 2990 | NA | MTT assay | Decrease (50 %) | Investigational | 27736754 |
| DrugRepV_5072 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | 10200 | NA | NA | Decrease (50 %) | Investigational | 29936152 |
| DrugRepV_5073 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | Hoti | NA | NA | Decrease (50 %) | Investigational | 29936152 |
| DrugRepV_5074 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | 10200 | NA | Survival assay | Increase | Investigational | 29936152 |
| DrugRepV_5075 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | Hoti | NA | Survival assay | Increase | Investigational | 29936152 |
| DrugRepV_5076 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | 10200 | NA | Real-time PCR | Decrease | Investigational | 29936152 |
| DrugRepV_5077 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | Hoti | NA | Real-time PCR | Decrease | Investigational | 29936152 |
| DrugRepV_5078 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | 10200 | NA | Survival assay | No significant effect | Approved | 29936152 |
| DrugRepV_5079 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | Hoti | NA | Survival assay | No significant effect | Approved | 29936152 |
| DrugRepV_5080 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | 10200 | NA | Real-time PCR | Decrease | Approved | 29936152 |
| DrugRepV_5081 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | Hoti | NA | Real-time PCR | Decrease | Approved | 29936152 |
| DrugRepV_5082 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | NA | NA | Real-time PCR | Decrease (100 Copies/ml) | Approved | 29584885 |
| DrugRepV_5083 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Crimean-Congo hemorrhagic fever virus | 86-07 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_5084 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Crimean-Congo hemorrhagic fever virus | 86-07 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_5085 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | Crimean-Congo hemorrhagic fever virus | 86-07 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_5086 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | Crimean-Congo hemorrhagic fever virus | 87-07 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_5087 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Crimean-Congo hemorrhagic fever virus | 87-07 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_5088 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | Crimean-Congo hemorrhagic fever virus | 87-07 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
| DrugRepV_5089 | S-Nitroso-N-acetylpenicillamine | NA | NA | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Immunoflourescence assay | Decrease (>90 %) | NA | 16632039 |
| DrugRepV_5090 | S-Nitroso-N-acetylpenicillamine | NA | NA | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Western blot | Decrease | NA | 16632039 |
| DrugRepV_5091 | S-Nitroso-N-acetylpenicillamine | NA | NA | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Real-time PCR | Decrease | NA | 16632039 |
| DrugRepV_5092 | IFN-alpha | Antiviral | Hepatitis C virus | Leukemia | Melanoma | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Western blot | Decrease | Investigational | 16372299 |
| DrugRepV_5093 | IFN-alpha | Antiviral | Hepatitis C virus | Leukemia | Melanoma | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Western blot | Decrease | Investigational | 16372299 |
| DrugRepV_5094 | IFN-alpha | Antiviral | Hepatitis C virus | Leukemia | Melanoma | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Fluorescence-based assay | Decrease (3 log FFU/ml) | Investigational | 16372299 |
| DrugRepV_5095 | IFN-alpha | Antiviral | Hepatitis C virus | Leukemia | Melanoma | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Fluorescence-based assay | No significant effect (2 fold FFU/ml) | Investigational | 16372299 |
| DrugRepV_5096 | IFN-alpha | Antiviral | Hepatitis C virus | Leukemia | Melanoma | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Real-time PCR | Decrease | Investigational | 16372299 |
| DrugRepV_5097 | IFN-alpha | Antiviral | Hepatitis C virus | Leukemia | Melanoma | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Real-time PCR | No significant effect | Investigational | 16372299 |
| DrugRepV_5098 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 29024765 |
| DrugRepV_5099 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (50 %) | Investigational | 29024765 |
| DrugRepV_5100 | 2-Deoxy-2-fluorocytidine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (50 %) | NA | 29024765 |
| DrugRepV_5101 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 29024765 |
| DrugRepV_5102 | 2-Chloroadenosine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Increase (-26 %) | NA | 29024765 |
| DrugRepV_5103 | 2-Deoxy-2-fluorocytidine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (98 %) | NA | 29024765 |
| DrugRepV_5104 | 2-C-Methylcytidine | NA | HCV | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (4 %) | Experimental | 29024765 |
| DrugRepV_5105 | 2-C-Methyluridine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Increase (-9 %) | NA | 29024765 |
| DrugRepV_5106 | 2-O-Methylcytidine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (7 %) | NA | 29024765 |
| DrugRepV_5107 | 2-O-Methyluridine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (7 %) | NA | 29024765 |
| DrugRepV_5108 | 3-Deazauridine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (19 %) | NA | 29024765 |
| DrugRepV_5109 | 5-Azacytidine | Antineoplastic and Immunomodulating Agents | Anemia | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (0 %) | Approved | 29024765 |
| DrugRepV_5110 | 5-Azidouridine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (28 %) | NA | 29024765 |
| DrugRepV_5111 | 5-Bromouridine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (1 %) | NA | 29024765 |
| DrugRepV_5112 | 5-Chlorouridine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (0 %) | NA | 29024765 |
| DrugRepV_5113 | 5-Fluorouridine | NA | Cancer | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (7 %) | Experimental | 29024765 |
| DrugRepV_5114 | 5-Methylcytidine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (6 %) | NA | 29024765 |
| DrugRepV_5115 | 6-Aza-2-thiouridine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (17 %) | NA | 29024765 |
| DrugRepV_5116 | 6-Azauridine | NA | Cancer | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (36 %) | NA | 29024765 |
| DrugRepV_5117 | 7-DMA | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (26 %) | NA | 29024765 |
| DrugRepV_5118 | 8-Azaadenosine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (92 %) | NA | 29024765 |
| DrugRepV_5119 | 8-Azidoadenosine | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (87 %) | NA | 29024765 |
| DrugRepV_5120 | ABT-333 | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (39 %) | Approved | 29024765 |
| DrugRepV_5121 | Balapiravir | Antiviral | Viral infection (Dengue and Hepatitis C, Chronic) | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (7 %) | Investigational | 29024765 |
| DrugRepV_5122 | BCX4430 | NA | Ebola virus | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (18 %) | Investigational | 29024765 |
| DrugRepV_5123 | Cordycepine | Anticancer | Leukemia | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (12 %) | Investigational | 29024765 |
| DrugRepV_5124 | Gleevec | Antineoplastic and Immunomodulating Agents | Leukemia | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (26 %) | Approved | 29024765 |
| DrugRepV_5125 | Lamivudine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Hepatitis B virus | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (24 %) | Approved | 29024765 |
| DrugRepV_5126 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (99 %) | Approved | 29024765 |
| DrugRepV_5127 | Mycophenolate Mofetil | Immunosuppressant | Organ rejection (immunosuppressants) | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (99 %) | Approved, Investigational | 29024765 |
| DrugRepV_5128 | NITD008 | Antiviral | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Increase (-23 %) | NA | 29024765 |
| DrugRepV_5129 | PSI-6130 | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Increase (-6 %) | NA | 29024765 |
| DrugRepV_5130 | PSI-6206 | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Increase (-1 %) | NA | 29024765 |
| DrugRepV_5131 | PSI-7976 | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (9 %) | NA | 29024765 |
| DrugRepV_5132 | PSI-7977 | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (4 %) | Approved | 29024765 |
| DrugRepV_5133 | R-1479 | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (15 %) | NA | 29024765 |
| DrugRepV_5134 | R-7128 | Antiviral | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Increase (-1 %) | Investigational | 29024765 |
| DrugRepV_5135 | RO-9187 | NA | NA | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (12 %) | NA | 29024765 |
| DrugRepV_5136 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (2 %) | Approved | 29024765 |
| DrugRepV_5137 | Stavudine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (26 %) | Approved, Investigational | 29024765 |
| DrugRepV_5138 | Favipiravir | Antiviral | Influenza virus | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (88 %) | Investigational | 29024765 |
| DrugRepV_5139 | Tenofovir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (0 %) | Approved, Investigational | 29024765 |
| DrugRepV_5140 | Zidovudine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome/AIDS | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (27 %) | Approved | 29024765 |
| DrugRepV_5225 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Neutral red uptake assay | Decrease (50 %) | Approved | 15026198 |
| DrugRepV_5226 | Ribamidine | NA | NA | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Neutral red uptake assay | Decrease (50 %) | Investigational | 15026198 |
| DrugRepV_5227 | 6-Azauridine | NA | Cancer | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Neutral red uptake assay | Decrease (50 %) | NA | 15026198 |
| DrugRepV_5228 | Selenazofurin | NA | NA | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Neutral red uptake assay | Decrease (50 %) | NA | 15026198 |
| DrugRepV_5229 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Neutral red uptake assay | Decrease (50 %) | Experimental | 15026198 |
| DrugRepV_5230 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | Spu 128/81 | NA | Neutral red uptake assay | Decrease (50 %) | Approved | 15026198 |
| DrugRepV_5231 | Ribamidine | NA | NA | Crimean-Congo hemorrhagic fever virus | Spu 128/81 | NA | Neutral red uptake assay | Decrease (50 %) | Investigational | 15026198 |
| DrugRepV_5232 | 6-Azauridine | NA | Cancer | Crimean-Congo hemorrhagic fever virus | Spu 128/81 | NA | Neutral red uptake assay | Decrease (50 %) | NA | 15026198 |
| DrugRepV_5233 | Selenazofurin | NA | NA | Crimean-Congo hemorrhagic fever virus | Spu 128/81 | NA | Neutral red uptake assay | Decrease (50 %) | NA | 15026198 |
| DrugRepV_5234 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | Crimean-Congo hemorrhagic fever virus | Spu 128/81 | NA | Neutral red uptake assay | Decrease (50 %) | Experimental | 15026198 |
| DrugRepV_5235 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | Hy-13 | NA | Neutral red uptake assay | Decrease (50 %) | Approved | 15026198 |
| DrugRepV_5236 | Ribamidine | NA | NA | Crimean-Congo hemorrhagic fever virus | Hy-13 | NA | Neutral red uptake assay | Decrease (50 %) | Investigational | 15026198 |
| DrugRepV_5237 | 6-Azauridine | NA | Cancer | Crimean-Congo hemorrhagic fever virus | Hy-13 | NA | Neutral red uptake assay | Decrease (50 %) | NA | 15026198 |
| DrugRepV_5238 | Selenazofurin | NA | NA | Crimean-Congo hemorrhagic fever virus | Hy-13 | NA | Neutral red uptake assay | Decrease (50 %) | NA | 15026198 |
| DrugRepV_5239 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | Crimean-Congo hemorrhagic fever virus | Hy-13 | NA | Neutral red uptake assay | Decrease (50 %) | Experimental | 15026198 |
| DrugRepV_5240 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Crimean-Congo hemorrhagic fever virus | UG3010 | NA | Neutral red uptake assay | Decrease (50 %) | Approved | 15026198 |
| DrugRepV_5241 | Ribamidine | NA | NA | Crimean-Congo hemorrhagic fever virus | UG3010 | NA | Neutral red uptake assay | Decrease (50 %) | Investigational | 15026198 |
| DrugRepV_5242 | 6-Azauridine | NA | Cancer | Crimean-Congo hemorrhagic fever virus | UG3010 | NA | Neutral red uptake assay | Decrease (50 %) | NA | 15026198 |
| DrugRepV_5243 | Selenazofurin | NA | NA | Crimean-Congo hemorrhagic fever virus | UG3010 | NA | Neutral red uptake assay | Decrease (50 %) | NA | 15026198 |
| DrugRepV_5244 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | Crimean-Congo hemorrhagic fever virus | UG3010 | NA | Neutral red uptake assay | Decrease (50 %) | Experimental | 15026198 |